Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting
Sponsor: Merck KGaA, Darmstadt, Germany
Listed as NCT01101776, this observational or N/A phase trial focuses on Multiple Sclerosis and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Jan 2019 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck Serono Australia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Box Hill, Australia , Bruce, Australia , Burwood, Australia , Chatswood, Australia , Clayton, Australia , Fitzroy, Australia , Footscray, Australia , Geelong, Australia , Heidelberg, Australia and 5 more locations